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Abstract
Angiogenesis and tumor expansion are associated
with extracellular matrix remodeling and involve
various proteases such as the plasminogen (Plg)/
plasminogen activator (PA) system. Recently, several
experimental data have implicated the plasminogen
activator inhibitor-1 (PAI-1) in tumor angiogenesis in
murine systems. However, little is known about PAI-1
functions in human skin carcinoma progression. By
generating immunodeficient mice (in Rag-1/ or nude
background) deleted for PAI-1 gene (PAI-1/), we have
evaluated the impact of host PAI-1 deficiency on the
tumorigenicity of two malignant human skin keratino-
cyte cell lines HaCaT II-4 and HaCaT A5-RT3 forming
low-grade and high-grade carcinomas, respectively.
When using the surface transplantation model, angio-
genesis and tumor invasion of these two cell lines are
strongly reduced in PAI-1–deficient mice as compared
to the wild-type control animals. After subcutaneous
injection in PAI-1/ mice, the tumor incidence is
reduced for HaCaT II-4 cells, but not for those formed
by HaCaT A5-RT3 cells. These data indicate that PAI-1
produced by host cells is an important contributor to
earlier stages of human skin carcinoma progression. It
exerts its tumor-promoting effect in a tumor stage–
dependentmanner, butPAI-1deficiency isnot sufficient
to prevent neoplastic growth of aggressive tumors of
the human skin.
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Introduction
The plasminogen (Plg)/plasminogen activator (PA) sys-
tem has been implicated in tissue remodelings associated
with both physiological and pathologic processes such as
wound healing, mammary gland involution, angiogenesis,
and cancer invasion. Serine proteases of the PA system
are produced both by stromal and neoplastic cells [1,2]. The
PA system is composed of several protein members: 1) Plg,
an inactive proenzyme; 2) urokinase PA (uPA) and 3) tissue-
type PA (tPA), two serine proteinases able to convert Plg
into plasmin; 4) uPA receptor (uPAR); and 5) plasminogen
activator inhibitors type I and type II (PAI-1 and PAI-2).
These extracellular proteases have multiple functions. Be-
sides their roles in extracellular matrix (ECM) degradation
and remodeling, they may also influence the degradation
and/or bioavailability of chemokines, cytokines, or their recep-
tors [3–5]. PAI-1 is a multifunctional glycoprotein containing
two active segments. One segment controls matrix proteol-
ysis by inhibiting the conversion of Plg into plasmin by uPA
and tPA. The other segment plays a role during cellular
adhesion and migration by blocking interaction between
vitronectin and different cell surface–associated molecules
such as uPA/uPAR complex and integrins (for review, see
Refs. [6,7]).
Based on extensive clinical and experimental studies, the
role of the PA system in cancer progression is now well
documented [8–12]. However, the mechanisms by which the
multifunctional PA system promotes malignant progression
are still not fully understood. In particular, the role of PAI-1,
which has been considered for a long time as a cancer
inhibitor, is still the object of a debate. The initially unexpected
findings that high PAI-1 levels have a prognostic impact of
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poor survival for patients suffering from a variety of different
cancers raised questions on the functions of PAI-1 [9,13]. In
this context, the surprising proangiogenic function of PAI-1
evidenced by transplanting murine tumor cells into PAI-1–
deficient (PAI-1/) mice has shed some lights on these
paradoxic clinical data [14,15]. Furthermore, controversial
data have been reported on the impact of genetic alterations
in PAI-1 levels on tumor progression. One study concluded
that neither PAI-1 deficiency nor PAI-1 overexpression
affects tumor invasion and metastases of B16 melanoma
cells [16]. Recently, lack of spontaneous phenotype in PAI-
1–deficient mice was found consistent with the observa-
tion that spontaneous transgenic breast cancer was unaf-
fected by PAI-1 deficiency [17]. In a sarcoma model, both
uPA and tPA appeared more crucial for tumor growth than
PAI-1 [11].
Altogether, these findings suggest that the tumor-
promoting effects of PAI-1 may be dependent on the tumor
type, the site of its production (tumor cells versus host cells),
and the stage of the cancer progression. Until now, all
studies investigating the impact of PAI-1 deficiency on tu-
mor growth have been performed by transplanting murine
tumor cells into syngeneic mice, or by interbreeding PAI-1–
deficient mice with transgenic mice developing oncogene-
driven tumors. However, up to now, no information is
available regarding the putative role of PAI-1 in human
skin or cervical carcinoma progression. To address this
question, we have generated immunodeficient PAI-1
knockout mice in two different genetic backgrounds [nude
or recombination activating gene-1 (Rag-1) –deficient
mice]. Human malignant cervical keratinocytes and human
HaCaT-Ras skin carcinoma cells displaying different inva-
sive potentials have been transplanted on a collagen
matrix or subcutaneously injected into these mice. In the
present study, we demonstrate that PAI-1 is an essential
factor of the host microenvironment, promoting early steps
of skin carcinoma progression.
Materials and Methods
Genetically Modified Mice
PAI-1–deficient mice (PAI-1/) and their correspond-
ing wild type mice (WT; PAI-1+/+) with a mixed genetic
background of 87% C57BL/6 and 13% 129 strain were
mated with Rag-1–deficient mice (Rag-1/: B6; 129S-
Rag-1tm/Mom/J) purchased from Charles Rivers Laboratories
(L’Arbresle, France). F1 offspring were heterozygous for
both genes. The F2 offspring of the F1 interbreeding were
screened by FACS analysis for the absence of CD4, CD8,
and CD3 (Becton Dickinson, San Diego, CA) or the pres-
ence of thy 1.2 expression (as positive control) (Becton
Dickinson) on whole blood lymphocytes (data not shown).
The resulting mice identified as Rag-1/ were screened
for PAI-1–null allele. DNA was extracted from tail biop-
sies (genomic DNA extraction kit from tissue; Macherey-
Nagel, Du¨ren, Germany), amplified by polymerase chain
reaction (PCR) with Taq DNA polymerase (Takara) and a
PCR mix including three primers to discriminate between
WT, heterozygous, and homozygous mice: PAI-2312
(5V-GACCTTGC CAAGGTGATGCTTGGCAAC-3V) and
PAI-2726 (5V-GAGTGGCCTGCTAGGAAATTCA TTC-3V)
annealing in the PAI-1 gene (accession no. M33960), and
PGKPA (5V-AA TGTGTCAGTTTCATAGCC-3V) annealing in
the knockout construct. The PCR conditions included an
initial denaturation step at 95jC for 5 minutes, followed by
35 cycles at 94jC for 1 minute, 60jC for 1 minute, 72jC for
1 minute, and a final extension step at 72jC for 5 minutes.
The reaction products were analysed by electrophoresis on
2% agarose gel. The size of the amplified fragment was
400 bp for WT mice, 190 and 400 bp for PAI-1+/ mice, and
190 bp for PAI-1/ mice. All animals used were 2 months
old and were maintained under specific pathogen-free con-
ditions, with 12-hour light/12-hour dark cycle and had free
access to food and water.
Nude mice were generated by backcrossing C57B16J/
129 PAI-1 heterozygous mice into the META/Bom
substrain of BALB/c for five passages. Littermate offspring
were made bymating a PAI-1+/META/Bom nu/nu male with
a PAI-1+/ female of the META/Bom nu/+ genotype. In all
experiments involving wild-type mice as controls, these were
littermates to the PAI-1 gene–deficient mice.
Cell Lines and Culture
The malignant HaCaT II-4 clone was derived from human
HaCaT keratinocytes after transfection with the mutated val-
12-Harvey-Ras oncogene (HaCaT-Ras cells) [18]. HaCaT
A5-RT3 clone was established by recultivation in vitro of
subcutaneous tumors derived from HaCaT-Ras cells and
retransplanted three times in vivo. These two cell lines with
HaCaT II-4 (forming well differentiated SCCs) and HaCaT
A5-RT3 (growing to poorly differentiated SCCs with local
lymph node metastases) display different tumorigenic poten-
tials [19]. The Caski cell line is an HPV16-transformed
cervical cell line [20].
Malignant HaCaT cells were cultivated in modified
Eagle’s medium containing a four-fold concentration of es-
sential amino acids and vitamins (GIBCO BRL, Paisley, UK),
10% fetal bovine serum (FBS) (GIBCO BRL), penicillin (100
U/ml), and streptomycin (100 mg/ml). The growth medium
used for CasKi cells was a 1:3 mixture of Ham’s F12/
Dulbecco’s modified Eagle’s medium (GIBCO BRL), supple-
mented with 0.4 mg/ml hydrocortisone (Sigma Chemical Co.,
St Louis, MO), 2 ng/ml epidermal growth factor (Sigma), 10%
FBS (GIBCO BRL), 2 mM L-glutamine (GIBCO BRL), 1 mM
sodium pyruvate (GIBCO BRL), penicillin (100 U/ml), strep-
tomycin (100 mg/ml) (GIBCO BRL), 5 mg/ml insulin (Sigma),
20 mg/ml adenine (Sigma), 5 mg/ml human transferrin
(Sigma), and 15 104 mg/ml 3,3V,5-triiodo-L-thyronine (Sig-
ma). Cells were maintained in a humidified incubator at 37jC
with 5% CO2.
For transplantation assay, cells (2 105) were plated on a
collagen gel (4 mg/ml type I collagen isolated from rat tail
tendons) inserted in Teflon rings (Renner GmbH, Darmstadt,
Germany) and maintained in culture for 1 day before grafting
in mice.
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Reverse Transcriptase PCR Analysis
Total RNA from HaCaT II-4 and HaCaT A5-RT3 cells
was extracted using the High Pure RNA isolation kit (Roche
Diagnostics, Mannheim, Germany). RT-PCR amplification
was performed using the GeneAmp Thermostable rTth
reverse transcriptase RNA PCR kit (Perkin Elmer Life
Sciences, Boston, MA), specific pairs of primers (5 pmol
each) (Table 1), and 10 ng of total RNA per 25 ml of reaction
mixture (final volume). Reverse transcription was performed
at 70jC for 15 minutes. For uPA and PAI-1 transcripts, PCR
amplification was run as follows: 15 seconds at 94jC,
20 seconds at 68jC, 10 seconds at 72jC (number of cycles
as indicated in Table 1), followed by a final 2-minute
extension step at 72jC. Other cycling conditions are the
followings: 20 seconds at 94jC, 30 seconds at 64jC,
20 seconds at 72jC for tPA, aV and b3 integrin; and
20 seconds at 94jC, 30 seconds at 60jC, and 20 seconds
at 72jC for uPAR and 28S. RT-PCR products were resolved
on 10% polyacrylamide gels and analysed using a Fluor-S
MultiImager (Bio-Rad, Hercules, CA) after staining with
Gelstar dye (FMC BioProducts, Heidelberg, Germany).
The selected primer pairs are described in Table 1.
Enzymatic Assay
HaCaT II-4 and HaCaT A5-RT3 cells were plated at
105 cells/well in a 12-well culture plate. After 2 days of
culture, cells were rinsed twice with PBS and left in serum-
free medium with or without Plg (5 mg/ml; Roche Diagnos-
tics), amiloride, a specific uPA inhibitor (200 mg/ml;
Sigma), or a2-antiplasmin (3 mg/ml; Sigma). After 24 hours
of incubation time, the conditioned media were harvested,
centrifuged for 5 minutes at 5103 g, and then concentrated
10-fold by centrifugation (Amicon Ultra-4 104 MW; Millipore,
Bedford, MA). Fifty microliters of 10-fold concentrated con-
ditioned media was incubated in 50 mM Tris/HCl, pH 7.4,
100 mM NaCl, 0.01% Tween-20, and 100 mM H-Ala-Phe-
Lys-AMC (Bachem, Weil am Rhein, Germany), a fluorogenic
plasmin substrate, for 200 seconds at 37jC. Fluorescence
was measured in a Microplate Fluorometer (SpectraMax
GeminiXS; Molecular Devices, Bedford, MA) at 380 nm
(excitation) and 460 nm (emission). Results are expressed
as fluorescent arbitrary unit normalized to cell DNA content.
Transplantation Assay in Mice
The cell-coated collagen gels were covered with a sili-
cone transplantation chamber (Renner GmbH) and im-
planted in toto onto the dorsal muscle fascia of mice as
described previously [14,21]. Three weeks later, transplants
were resected, embedded in Tissue Tek (Miles Laborato-
ries, Inc., Naperville, IL), and frozen in liquid nitrogen for
cryostat sectioning.
In all assays, the take rate and growth of transplants
were verified by classic histology, and some samples were
not taken into account. The exclusion criteria were the loss
of transplantation chamber, the absence of cells on top of
the collagen gel, and the failure of collagen gel adherence
onto the host tissue with the consequence of poor cell
growth. Based on the two latter parameters, 11% of samples
resected from WT mice and 35% of samples resected from
PAI-1/ mice were excluded (in both immunodeficient
backgrounds). These differences reflect the lower re-
modeling and infiltration of the collagen gel by host cells in
PAI-1/ mice. Chambers were lost in 7% of WT mice and
11% of PAI-1/ mice.
Subcutaneous Injection
Cells were inoculated subcutaneously (2 106 cells in
200 ml of culture medium per site) into each flank of the
animals. Tumor incidence was defined as the percentage of
mice presenting a tumor having a volume of at least 50 mm3.
Table 1. Sequence of Primers Used for RT-PCR Studies.
Gene (Accession No.) Position Oligonucleotide Sequence (5V–3V) Cycles (n)
28S (U13369) 12403F GTTCACCCACTAATAGGGAACGTGA 17
12614R GATTCTGACTTAGAGGCGTTCAGT
PAI-1 (M16006) 464F AGGGCTTCATGCCCCACTTCTTCA 30
655R AGTAGAGGGCATTCACCAGCACCA
uPA (NM_002658) 1122F ACTACTACGGCTCTGAAGTCACCA 30
1321R GAAGTGTGAGACTCTCGTGTAGAC
tPA (NM_033011) 362F CAGCAGGCCCTGTACTTCTC 37
633R GGCTTTGAGTCTCGATCTGG
uPAR (U08839) 901F CTGGAGCTTGAAAATCTGCCG 30
1057R GGTTTTTCGGTTCGTGAGTGC
aV (NM_002210) 2328F CGAAACAATGAAGCCTTAGCAAGA 30
2605R GGACTCGAGACTCCTCTTATCTCA
b3 (NM_000212) 782F GGCTACAGTCTGTGATGAAAAGAT 35
1153R CGGATTTTCCCATAAGCATCAACA
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Immunofluorescence Staining
Cryostat sections (6 mm thick) were fixed in acetone at
20jC and 80% methanol at 4jC for 10 minutes, permeabil-
ised in 1% Triton X-100 for 10 minutes, and then incubated
with the primary antibodies (Abs). Abs against fibrinogen
(goat antimouse) and against VEGF (rabbit antihuman) were
purchased from Nordic Immunology (Tilburg, The Nether-
lands) and Santa Cruz Biotechnology (Santa Cruz, CA),
respectively. For double immunofluorescence labeling stud-
ies, sections were first incubated for 2 hours at 37jC with the
two primary Abs: anti– type IV collagen Ab (guinea pig
polyclonal Ab) [22] and anticytokeratin Ab (rabbit poly-
clonal Ab, diluted 1/200, catalog no. Z0622; Dako, Glostrup,
Denmark). The sections were washed in PBS (3 
10 minutes) before the incubation with appropriate second-
ary Abs conjugated to fluorescein– isothiocyanate (FITC) or
tetramethyl-rhodamine isothiocyanate (TRITC): goat anti–
guinea pig IgG (diluted 1/100; ICN Costa Mesa, CA) and
monoclonal antirabbit Abs (diluted 1/40; Dako) were applied
for 30 minutes at room temperature. The sections were
washed three times in PBS for 10 minutes each and cover-
slips were mounted with Aqua Polymount (Polysciences,
Warrington, FL). The specific labeling was observed using an
inverted microscope equipped with epifluorescence optics.
The assessment of apoptotic cell death was performed
by detecting DNA strand breaks by the terminal deoxy-
nucleotidyl transferase (TdT)–mediated dUTP nick-end
labeling (TUNEL) method. Cryostat sections fixed in 4%
paraformaldehyde for 20 minutes and in methanol for
5 minutes were stained for apoptosis following the manufac-
turer’s instructions (Roche Diagnostics).
Morphometric Analysis of Angiogenesis and Tumor
Cell Invasion
Morphometric assessment of angiogenesis was scored
as previously described [23]. A score of () means that
vessels were undetected in the collagen gel. When blood
vessels infiltrate the collagen gel and get into close contact
with the malignant epithelial layer, a score of (++) is
assigned. A score of (+++) indicates that vessels infiltrated
the tumor parenchyma so that invasive epithelial tumor
sprouts and vessels are intermingled. Morphometric mea-
surements of tumor cell invasion (average distance of inva-
sion) were performed by using a computer-assisted image
analysis system (Quantimet 600 imaging; Leica, Van Hop-
plynus, Brussels, Belgium). The depth of tumor invasion was
determined by measuring the distance between the top of
the tumor cell layer and the deepest tumor sprouts [24]. An
average distance of invasion was calculated from at least
10 measurements per tumor section.
Statistical Analysis
DATA were analyzed on a computer (GraphPad Prism).
The chi-square analysis was used to determine whether
there were significant differences in angiogenesis scores
between control and genetically modified mice. Quantifica-
tion results of tumor invasion were statistically analysed
using two-tailed Student’s t test. Tumor incidence data were
analysed with the log rank test. For all experimental con-
ditions, P < .05 was considered as significant.
Results
Tumor Cell Transplantation Into PAI-1/ and WT
Nude Mice
The invasive and angiogenic phenotypes of two malig-
nant human cutaneous keratinocytes (HaCaT II-4 and
HaCaT A5-RT3) were compared in the surface trans-
plantation assay. We first compared the production of
various components of the Plg/plasmin cascade in these
two cell lines. An RT-PCR analysis revealed that these cells
expressed the different components of the PA system (uPA,
uPAR, and PAI-1) at similar levels (Figure 1). Low levels of
tPA mRNA were detected in both cell lines (Figure 1). To
determine PA activities, hydrolysis of plasmin fluorogenic
substrate was quantified in the medium conditioned by
cells. Addition of exogenous Plg led to a strong hydrolysis
of the plasmin substrate, which was completely inhibited by
a2-antiplasmin. The plasmin activity observed on Plg addi-
tion was similar in medium conditioned by HaCaT II-4
(fluorescent arbitrary unit/mg DNA = 416.8 ± 36.1) and
HaCaT A5-RT3 (fluorescent arbitrary unit/mg DNA = 357 ±
56.7) (P > .05). A 70% reduction of plasmin activity was
observed in both conditioned media after addition of ami-
loride, an uPA inhibitor (fluorescent arbitrary unit/mg
DNA = 124.4 ± 20.7 and 113.9 ± 21.7 for HaCaT II-4 and
HaCaT A5-RT3, respectively) (P < .01). This demonstrates
that Plg-to-plasmin conversion is mainly mediated by uPA
in both cell types. Similar amounts of PAI-1 were produced
by both cell lines as assessed by ELISA (3.2 and 3.4 ng/ml
for HaCaT II-4 and HaCaT A5-RT3, respectively). Because
Figure 1. Expression of components of the Plg/plasmin cascade and of
integrins by HaCaT clones. Total RNA were extracted from HaCaT A5-RT3
(1) and HaCaT II-4 (2). RT-PCR analyses were performed for PAI-1 (A), uPA
(B), uPAR (C), tPA (D), 3 subunit (E), and aV subunit (F) of integrins. In some
assays, RNA isolated from glioblastomas (D) or human umbilical vein cells
(HUVECs) (E) have been added as positive controls. 28S ribosomal RNA is
shown as a loading control (G). The expected sizes of amplified mRNAs are
indicated on the right. g = glioblastomas; h = HUVEC.
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PAI-1 function may be related to its capacity to interact with
aVb3 integrin, the expression of these two integrin subunits
was analyzed by RT-PCR (Figure 1). Although both cell
lines produced the aV subunit at similar extent, they did not
express the b3 subunit (Figure 1).
After this expression profiling analysis, cells cultured on a
collagen gel were implanted onto the dorsal muscle fascia of
WT and PAI-1/ nude mice. Such a grafting in WT mice led
to a remodeling of the collagen matrix, infiltration by host-
derived cells, and a progressive replacement by a highly
vascularized granulation tissue [14,25]. Three weeks after
grafting into WT mice, both cell types formed a multilayered,
poorly organized epithelium infiltrated by stromal strands
containing capillaries (Figure 2A). In sharp contrast, when
HaCaT A5-RT3 or HaCaT II-4 cells were implanted into
PAI-1–deficient mice, a significant reduction in host connec-
tive tissue formation and in tumor growth and invasion was
observed. As a consequence, most of the collagen matrix
persisted below the stratified epithelial layers (Figure 2A).
Cancer invasion was determined by measuring the maxi-
mal depth of penetration of individual tumor sprouts and
by calculating the average distance of invasion. Both HaCaT
II-4 and A5-RT3 penetrated more deeply into WT host tissue
(231.7 ± 15.97 mm and 585.4 ± 109.8 mm , respectively) than
into PAI-1–deficient tissue (103.2 ± 7.72 mm and 210.6 ±
53.82 mm, respectively) (P < .02) (Figure 3, a and b).
Tumor angiogenesis was visualized after staining for
collagen type IV to delineate capillary basement membrane
Figure 2. In vivo growth and invasive behavior of malignant human
keratinocytes. (A) HaCaT II-4 (a and d), HaCaT A5-RT3 (b and e), and
CasKi (c and f) cells were transplanted for 3 weeks into WT (a–c) and PAI-
1/ (d– f) nude mice. (B) HaCaT II-4 (a and c) and HaCaT A5-RT3 (b and d)
cells were transplanted for 3 weeks into WT (a and b) and PAI-1/ (c and d)
Rag-1/ mice. Histological sections were stained with hematoxylin and
eosin. C = carcinoma cells; G = collagen gel; H = host connective tissue.
Original magnification,200.
Figure 3. Morphometric assessment of tumor cell invasion implanted into nude or Rag-1/ mice. HaCaT II-4 (a and d), HaCaT A5-RT3 (b and e), and CasKi (c)
tumor cells were grafted for 3 weeks into PAI-1/ (white bars) and control (black bars) mice in nude (a–c) or Rag-1/ (d and e) background. Tumor cell invasion
was estimated by measuring the distance between the top of the tumor to the deepest front of tumor spread. n = number of animals per group. *P V .02, ***P V
.0001, Student’s t test. Data are expressed as mean ± standard error of the mean.
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(Figure 4A) or for CD31/PECAM (data not shown) and
semiquantitatively scored (Figure 5). Whereas vessels had
reached the epithelial–stromal border and had penetrated
the tumor parenchyma in wild-type animals, they stayed
apart in PAI-1–deficient mice separated from the epithelium
by the remnant collagen matrix. In accordance with their
more aggressive phenotype, about 70% of WT mice grafted
with HaCaT A5-RT3 cells were scored as (+++) (Figure 5b),
whereas all HaCaT II-4 tumors were scored as (++) in WT
mice (Figure 5a). After transplantation into PAI-1/ nude
mice, a reduction of tumor vascularization was detected
for both cell types. In the absence of host PAI-1, none of
the HaCaT A5-RT3 tumors was scored (+++) and 50% of
samples were scored () and (++) (P < .01) (Figure 5b). Most
of the HaCaT II-4 tumors (63%) were scored () (P < .01)
(Figure 5a). Therefore, PAI-1/ mice exhibited significantly
reduced tumor invasion and vascularization for both squa-
mous carcinoma cells in comparison to WT mice.
To determine whether the tumor-promoting effect of
PAI-1 is specific to the type of tumor cell used, the behavior
of malignant human cervical keratinocytes (Caski cells) was
investigated (Figures 2A and 4A). Tumor tissues were
developed, exhibiting about the same thickness (204.9 ±
37.41 mm in PAI-1/ vs 246.7 ± 20.05 mm in WT mice;
P > .05) although without pronounced invasion and were
vascularized to a similar degree (score ++) in both geno-
types (Figures 3c and 5c). Vascularization, however, was
more pronounced at the tumor border in WT than in PAI-1–
deficient animals.
Tumor Cell Transplantation Into PAI-1/ and
WT Rag-1/ Mice
We next investigated the angiogenic and invasive phe-
notypes of HaCaT A5-RT3 and HaCaT II-4 cells in another
PAI-1/ and WT background, the Rag-1/ mice. In WT
mice, the histologic aspect of the HaCaT II-4 and HaCaT A5-
RT3 tumors was similar to that observed in nude mice. Lack
of host PAI-1 resulted in a significant reduction of tumor
development (Figures 2B and 3, d and e) and vasculariza-
tion (Figures 4B and 5, d and e) for both tumor types. Again,
the distance of tumor invasion as well as the tumor mass
were higher in WT mice than in PAI-1/ mice (368.3 ±
56.68 mm vs 95.52 ± 7.37 mm for HaCaT II-4 cells, and
451.5 ± 54.41 mm vs 150.9 ± 16.58 mm for HaCaT A5-RT3
cells) (P < .0001) (Figure 3, d and e). Similarly, the scoring of
tumor vascularization revealed a reduced angiogenic re-
sponse in the absence of host PAI-1 (Figure 5, d and e).
Immunohistochemical Analysis of Tumor Transplants
We carried out an immunohistochemical analysis of
tumors transplanted into PAI-1–proficient or –deficient
mice, in both genetic backgrounds (nude or Rag-1/).
We first investigated the deposition of fibrin as an end-point
of a plasmin-mediated fibrinolysis and as a provisional
matrix for cell migration and invasion. Lack of host PAI-1
did not lead to any obvious modification of fibrin(ogen)
deposition, suggesting that fibrinolysis was not changed in
the absence of PAI-1 (data not shown). Although a de-
crease of VEGF production has been reported in the
absence of PAI-1 [15,26], no difference of VEGF staining
was evidenced in our transplantation system (data not
shown). Similarly, TUNEL stainings for apoptotic cells indi-
cated that the extent of apoptosis was always low in the
cancer cell layers, in endothelial cells of blood vessels
associated to the stromal strands of WT tumors, or in blood
vessels remaining below the collagen gel in PAI-1/ mice
(data not shown).
Subcutaneous Growth of Cells Injected Into WT or
PAI-1/ Mice
The in vivo tumorigenicity of the two HaCaT variants
was next evaluated by subcutaneous inoculation into
PAI-1/ mice and their control counterpart, in both nude
and Rag-1/ backgrounds. As shown in Figure 6, the
tumor incidence in nude PAI-1/ mice injected with HaCaT
II-4 was significantly decreased as compared to that ob-
served in WT mice (P < .05). Indeed, 38 days after cell
injection, HaCaT II-4 cells gave rise to 100% tumors in WT
mice and 62.5% in PAI-1–deficient mice (Figure 6A). A
reduction of tumor incidence was also observed in the
Rag 1/ background (Figure 6B). In sharp contrast, within
2 or 3 weeks, the more aggressive HaCaT A5-RT3 cells gave
Figure 4. Immunofluorescence labeling of malignant keratinocytes and
vessels in transplants grafted in nude (A) or Rag-1/ (B) mice. (A) HaCaT II-
4 (a and d), HaCaT A5-RT3 (b and e), and Caski (c and f) cells were
implanted for 3 weeks into WT (a–c) and PAI-1/ (d– f) nude mice. (B)
HaCaT II-4 (a and c) and HaCaT A5-RT3 (b and d) cells were grafted for
3 weeks into WT (a and b) and PAI-1/ (c and d) Rag-1/ mice. Malignant
cells were detected on cryostat sections by using anticytokeratin Ab (green),
and vessels were detected using an anticollagen type IV Ab (red). At all times
after grafting, collagen type IV labelings were codistributed with endothelial
cells recognized by antimouse platelet endothelial cell adhesion molecule
(PECAM) immunostaining (data not shown). C = carcinoma cells; G =
collagen gel; H = host connective tissue. Original magnification,100.
62 PAI-1 and Human SCC Progression Maillard et al.
Neoplasia . Vol. 7, No. 1, 2005
rise to 80% to 100% of tumors in mice regardless of PAI-1
status and in both nude and Rag-1 backgrounds (Figure 6).
To better define the process leading to a reduction of
HaCaT II-4 tumor incidence in PAI-1/ mice, tumor growth
was also evaluated. We observed that once the tumors were
established, the increase of tumor volumes was identical in
both genotypes and was not dependent on the expression
levels of host PAI-1 (data not shown). These data suggest
that PAI-1 displays a growth-promoting effect for poorly
aggressive cancer cells during early stages of tumor
growth, but is dispensable when the tumor is undergoing
expansion. In the case of more aggressive tumors (HaCaT
Figure 5. Semiquantitative analysis of angiogenesis of tumors transplanted into nude or Rag-1/mice. HaCaT II-4 (a and d), HaCaT A5-RT3 (b and e), and CasKi
(c) tumor cells were grafted for 3 weeks into PAI-1/ (white bars) and WT (black bars) mice in a nude (a–c) or Rag-1/ (d and e) background. Morphometric
assessment of angiogenesis was scored as follows: vessels undetected in the collagen gel: score (); blood vessels infiltrating the collagen gel and getting in close
apposition to the epithelial layer: score (++); and blood vessels intermingling with invasive epithelial tumor sprouts: score (+++). n = number of animals per group.
Chi-square analysis was used; P is indicated.
Figure 6. Analysis of HaCaT II-4 and HaCaT A5-RT3 malignant cutaneous cell tumorigenicity in PAI-1/ and WT nude (A) and Rag-1/ (B) mice. The incidence
corresponds to the percentage of animals bearing palpable tumors (volume >50 mm3). Each experimental group includes 10 mice.
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A5-RT3 cells), consistent with the effect on tumor incidence
(Figure 6), the growth rate was similar in the absence or
presence of host PAI-1 (data not shown).
Discussion
The onset of invasion represents an early step in the conver-
sion of a carcinoma in situ to a malignant squamous cell
carcinoma (SCC) with the capacity to spread and to even-
tually metastasize. Angiogenesis and tumor vascularization
appear as a crucial prerequisite for invasion [21,27]. Angio-
genesis involves a tightly controlled orchestration of
complex interactions between tumor cells, host cells, soluble
factors, and ECM components that lead to the formation of
new blood vessels. The specific functions of the in vivo
microenvironment in controlling the invasive and angiogenic
phenotypes of tumor cells are still poorly understood. How-
ever, the recent generation of targeted gene–deficient mice
has been helpful to identify individual genes playing a key
role during tumor growth and vascularization. In this context,
PAI-1 hasbeen identified as a crucial element of the Plg/PA
system controlling in vivo tumor angiogenesis [14,15,23].
Although much has been learned on murine tumor develop-
ment utilizing PAI-1/ mice, no experimental data are
available regarding the role of PAI-1 in human cancer
progression. In the present study, immunodeficient PAI-1/
 mice have been generated in two different genetic back-
grounds (Rag-1/ or nude nu/nu). Two separate sets of
experiments including 8 to 24 mice per genotype (PAI-1/
and their corresponding WT) in both immunodeficient ge-
netic backgrounds demonstrated the dramatic effect of host
PAI-1 absence on SCC growth and vascularization. The
present study provides evidence that PAI-1 in these models
is a crucial determinant of tumor microenvironment in regu-
lating and enhancing early stages of human skin carcinoma
invasion.
When two different human cell lines were transplanted as
a precultured epithelium on a collagen gel (surface trans-
plantation system), both tumor invasion and vascularization
were reduced in PAI-1–deficient mice. In accordance with
their more aggressive phenotype, HaCaT A5-RT3 trans-
plants were much more vascularized (score +++) in WTmice
than HaCaT II-4 transplants. A significant reduction of the
invasive and angiogenic phenotypes of both HaCaT II-4
and HaCaT A5-RT-3 cells was determined by objective
morphometric quantification. This important effect of PAI-1
deficiency on tumor progression emphasizes the key role
played by host cells during this process. With low tumor cell
numbers, PAI-1 produced by neoplastic cells is not sufficient
to circumvent host deficiency. Indeed, by transfecting malig-
nant keratinocytes with PAI-1 cDNA, we previously showed
that PAI-1 produced by tumor cells, even at high concentra-
tion, did not overcome the absence of PAI-1 in the host tissue
[24]. The present data provide the first experimental evi-
dence for a role of stromal PAI-1 in human skin cancer
invasion and vascularization.
Although the precise mechanism of PAI-1 action is not
well understood, several lines of evidence indicate that PAI-1
effects result from a tight control of extracellular proteolysis
and/or a regulation of cell detachment and migration by its
interaction with vitronectin and integrins [28,29]. By using
adenoviral delivery of mutated forms of PAI-1, we have
previously demonstrated that PAI-1 facilitates tumor angio-
genesis [23,30] or laser-induced choroidal angiogenesis
[31] by inhibiting proteolytic activity rather than by interac-
ting with vitronectin. In the present study, the lack of b3
integrin subunit expression by the cells used is consistent
with a PAI-1–mediated regulation of angiogenesis without
involvement of integrins. The requirement of a good balance
between PA and PAI-1 is supported by recent data show-
ing that the proangiogenic and antiangiogenic effects of
PAI-1 are dose-dependent [24,30,32,33]. In other models,
PAI-1 effects have been ascribed to both antiprotease and
vitronectin-binding functions [28,34]. Because PAI-1 is a
multifunctional molecule, it is likely that its mechanisms of
action are dependent on the tumor types and/or on the stage
of cancer progression. Host PAI-1 did not affect the extent of
apoptosis of tumor cells and/or stromal cells as assessed by
TUNEL stainings (data not shown). This is consistent with a
previous report of recombinant PAI-1 administration into
mice bearing melanomas [33]. In vivo studies have reported
a decrease in VEGF expression in the absence of PAI-1
[15,26]. However, by immunohistochemical analysis, similar
VEGF stainings were detected in tumor cell transplants in the
absence or presence of PAI-1. We cannot exclude the
possibility that VEGF produced by tumor cells can compen-
sate for a putative regulation of stromal VEGF expression in
the absence of PAI-1. However, our data are in accordance
with the identical levels of both VEGF transcripts and pro-
teins evidenced in aortic endothelial cells isolated from WT
and PAI-1/mice [35]. It has been proposed that alterations
in the rate of cell proliferation in PAI-1/ endothelial cells
may affect vessel formation and stability [35]. However, by
using the surface transplantation system, similar numbers of
vessels were detected below the collagen gels in both WT
and PAI-1/ mice, thus reflecting an identical angiogenic
response induced below the transplant in both genotypes
[14]. This suggests that inhibition of angiogenesis is more
related to impaired ability of endothelial cells to infiltrate an
ECM or the tumor parenchyma rather than to an aberrant
proliferation rate. This is consistent with the defective
spreading of endothelial cells from aortic fragments issued
from PAI-1/mice [30]. The impaired angiogenesis was not
related to the use of a collagen type I matrix because tumor
cell implantation in the presence of Matrigel led to similar
dependency on host PAI-1 [24].
Cells were also subcutaneously inoculated into WT or
PAI-1/ mice. The lack of PAI-1 significantly reduced the
incidence of subcutaneous tumors derived from poorly ag-
gressive HaCaT II-4 cells, but not the incidence of tumors
derived from the more aggressive HaCaT A5-RT3 cells.
However, in both cases, once implanted, the proliferation
rate of tumors was not dependent on the PAI-1 status of host
tissue. These data emphasize the importance of PAI-1 in the
early steps of cancer progression and confirmed our recent
study using murine PDVA cells [24]. A similar observation
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was already done for stromelysin-3 (MMP-11), which
appears to control tumor cell apoptosis [36–38]. Such a
specific effect of PAI-1 in early events of cancer progression
rather than during the course of cancer expansion may
provide an explanation for some of the apparently contradic-
tory reports in the literature. Also, the number of trans-
planted/injected tumor cells and their production of tumor
cell–derived PAI-1 may account for the differences seen in
surface transplants (low cell number) and subcutaneous
tumors (10 times higher injected cell number) concerning
the effects on tumor growth and invasion. In addition, the
absence of PAI-1 effect on the evolution of tumors induced
by human cervical CasKi cell transplantation suggests that
PAI-1 is not a universal proangiogenic factor and that its
effect may be tumor type–dependent or tumor stage–de-
pendent [6].
In conclusion, our data provide new insights into the
function of an individual component of the Plg/PA system,
host PAI-1, in specific steps of human cancer implantation.
Interestingly, it extends the importance of PAI-1 to human
skin carcinomas.
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